<DOC>
	<DOCNO>NCT02323646</DOCNO>
	<brief_summary>The primary objective study determine safety efficacy two vaginal dos Proellex administer 2 course treatment ( 18 week ) , separate Off-Drug Interval ( ODI ) , premenopausal woman symptomatic uterine fibroid .</brief_summary>
	<brief_title>A Phase 2 , Study Evaluate Safety Efficacy Proellex® ( Telapristone Acetate ) Administered Vaginally Treatment Uterine Fibroids</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Otherwise healthy adult female 18 47 year Subject history least 3 regular menstrual cycle menorrhagia due uterine fibroid . Subject must uterine fibroid . Agreement attempt become pregnant trial Agreement use sanitary pad provide throughout course study , tampon use prohibit Ability complete daily subject diary study procedure compliance protocol Has negative pregnancy test Screening Baseline visit , subsequent study visit A Body Mass Index ( BMI ) 18 45 inclusive Confirmed &gt; 80 mL menstrual blood loss cause uterine fibroid Subject postmenopausal woman , define either ; six ( 6 ) month ( immediately prior screen visit ) without menstrual period , prior hysterectomy and/or oophorectomy . Subject pregnant lactating attempt expect become pregnant entire study period Received investigational drug 30 day prior screen study Subject history PCOS Concurrent use testosterone , progestin , androgen , estrogen , anabolic steroid , DHEA hormonal product least 2 week prior screen study Use oral contraceptive precede 30 day . Use DepoProvera® precede 10 month . Use GnRHas ( e.g . Lupron Depot ) within 3 month first dose study drug ( Lupron Depot must washout period 3 month ) Has IUD place Known suspect carcinoma breast reproductive organ Recent history ( within past 6 month ) alcoholism drug abuse Clinically significant abnormal finding screen examination laboratory assessment condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>uterine fibroid</keyword>
	<keyword>leiomyoma</keyword>
	<keyword>fibroid tumor</keyword>
	<keyword>fibroma</keyword>
</DOC>